Febit Slashes Headcount, Kills Sequence Capture, Expression Offerings in Favor of miRNA Play
June 29, 2010
Febit Slashes Headcount, Kills Sequence Capture, Expression Offerings in Favor of miRNA Play
The cuts were necessary to take advantage of a "window of opportunity" in miRNA discovery that could enable the firm to enter the molecular diagnostics market.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.